CCND1 is also frequently co-amplified with FGF19 in head and neck squamous cell carcinoma, amplification of which was seen in 18 (35%) of patients in our cohort—FGF19 is involved in HNSCC tumorigenesis and may be useful as a target for therapy (46). This evidence concerns the gene FGF19 and head and neck squamous cell carcinoma.